

# Psychopharmacologia

## Editorial Board

D. Brøvet, Sassari · J. O. Cole, Boston · J. Delay, Paris · J. Elkes, Baltimore  
 M. Hamilton, Leeds · H. Isbell, Lexington · E. Jacobsen, København  
 M. E. Jarvik, Los Angeles · S. S. Kety, Boston · C. Kornetsky, Boston · E. Rothlin †, Basel  
 M. Shepherd, London · Hannah Steinberg, London · E. Strömrgren, Risskov  
 A. Wikler, Lexington

## Managing Editors

J. O. Cole · M. Hamilton · E. Jacobsen · C. Kornetsky

## Advisory Board

### Neurophysiologia

F. Bremer, Bruxelles  
 J. C. Eccles, Buffalo  
 A. Fessard, Paris  
 G. W. Harris, London  
 G. Moruzzi, Pisa  
 J. Z. Young, London

### Neuropharmacologia

M. Adler, Philadelphia  
 P. B. Bradley, Birmingham  
 A. Carlsson, Göteborg  
 H. Coper, Berlin  
 E. Domino, Ann Arbor  
 D. Efron, Chevy Chase  
 U. S. von Euler, Stockholm  
 W. S. Feldberg, London  
 S. Garattini, Milano  
 J. Harvey, Iowa City  
 L. E. Hollister, Palo Alto  
 O. Hornykiewicz, Toronto  
 E. Hosoya, Tokyo  
 S. Irwin, Portland  
 K. F. Killam, Palo Alto  
 I. P. Lapin, Leningrad  
 L. Lasagna, Rochester  
 E. Marley, London  
 W. R. Martin, Lexington  
 H. O. Schild, London  
 S. Sjöqvist, Stockholm  
 F. Sulser, Nashville  
 R. Taber, Bloomfield  
 A. Weissmann, Groton, Conn.  
 T. Yanagita, Kawasaki  
 E. Zaimis, London

### Neurochimia

S. Barondes, La Jolla  
 H. Blaschko, Oxford  
 J. Glowinski, Paris  
 D. Richter, Epsom  
 R. Rodnight, London  
 S. Udenfriend, Bethesda  
 H. Weil-Malherbe, Washington

### Neurologia

H. Gastaut, Marseille  
 P. van Gehuchten, Bruxelles

### Psychiatria

J. Angst, Zürich  
 H. Brill, New York  
 P. Deniker, Paris  
 P. Dick, Genève  
 M. Fink, New York  
 F. Flügel, Erlangen  
 S. Gershon, New York  
 H. Hippus, München  
 J. Jaffe, Washington  
 R. T. Jones, San Francisco  
 G. Klerman, Boston  
 N. S. Kline, Orangeburg  
 M. H. Lader, London  
 A. J. Lewis, London  
 O. Lingjærde, Oslo  
 P. Pichot, Paris  
 K. Rickels, Philadelphia  
 J. M. Rose, Leeds

J. Schildkraut, Boston  
 C. Shagass, Philadelphia  
 J. R. Smythies, Edinburgh  
 O. Vinar, Praha

### Psychologia

J. Appel, Chicago  
 H. Barry III, Pittsburgh  
 P. Carlton, New Brunswick  
 C. K. Connors, Boston  
 P. B. Dews, Boston  
 A. DiMascio, Boston  
 H. J. Eysenck, London  
 S. Fisher, Boston  
 S. C. Goldberg, Chevy Chase  
 S. Grossman, Chicago  
 H. Hanson, West Point  
 H. E. Hill, Lexington  
 C. R. B. Joyce, Basel  
 M. Katz, Chevy Chase  
 R. Kelleher, Boston  
 V. Laties, Rochester  
 A. Latz, Tel-Aviv  
 R. Lipman, Rockville  
 A. Lubin, La Jolla  
 A. E. Maxwell, London  
 J. L. McGaugh, Irvine  
 N. Mello, Washington  
 A. Mirsky, Boston  
 S. Norton, Kansas City  
 D. Overton, Philadelphia  
 C. Schuster, Chicago  
 A. Summerfield, London  
 T. Thompson, Minneapolis  
 O. Zangwill, Cambridge

Volume 27 · 1972



SPRINGER-VERLAG · BERLIN · HEIDELBERG · NEW YORK

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1972

## Contents

|  |     |
|--|-----|
| Subject Index . . . . .  | VI  |
| Abbatiello, E. R., see Gianutsos, G. . . . .   | 117 |
| Amposta, B., see Sansone, M., <i>et al.</i> . . . .  | 313 |
| Atsmon, A., Blum, I., Steiner, M., Latz, A., Wijssenbeek, H.: Further Studies<br>with Propanol in Psychotic Patients: Relation to Initial Psychiatric State,<br>Urinary Catecholamines and 3-Methoxy-4-Hydroxyphenylglycol Excretion . . . . . | 249 |
| Ayhan, I. H., Randrup, A.: Role of Brain Noradrenaline in Morphine-Induced<br>Stereotyped Behaviour . . . . .  | 203 |
| Bear, H. D., see Davis, M. . . . .   | 29  |
| Becker-Carus, Ch., Kimball, S. D., Gillich, U., Matussek, N.: Wirkung von<br>Alphamethyltyrosin auf das Lernverhalten und die Hippocampusaktivität . . . . .   | 53  |
| Bloom, J. M., see McFarlain, R. A. . . . .   | 85  |
| Blum, I., see Atsmon, A., <i>et al.</i> . . . .  | 249 |
| Bowers, M. B., Jr., see Kupfer, D. J. . . . .  | 183 |
| Breese, G. R., see Cooper, B. R., <i>et al.</i> . . . .  | 99  |
| Broermann, J., see Rating, D., <i>et al.</i> . . . .   | 349 |
| Brown, H.: Possible Anticholinesterase-Like Effects of Trans (-)- $\Delta^8$ - and - $\Delta^9$ -<br>Tetrahydrocannabinol as Observed in the General Motor Activity of Mice . . . . .  | 111 |
| Brown, K., see Warburton, D. M. . . . .  | 275 |
| Calhoun, W. H., see Kulig, B. M. . . . .   | 233 |
| Chen, Ch.-Sh.: A Further Note on Studies of Acquired Behavioural Tolerance<br>to Alcohol . . . . .   | 265 |
| Cooper, B. R., Breese, G. R., Howard, J. L., Grant, L. D.: Enhanced Behavioral<br>Depressant Effects of Reserpine and $\alpha$ -Methyltyrosine after 6-Hydroxy-<br>dopamine Treatment . . . . .  | 99  |
| Coper, H., see Rating, D., <i>et al.</i> . . . .   | 349 |
| Covi, L., see Uhlenhuth, E. H., <i>et al.</i> . . . .  | 67  |
| Crowley, T. J.: Dose-Dependent Facilitation or Suppression of Rat Fighting by<br>Methamphetamine, Phenobarbital, or Imipramine . . . . .   | 213 |
| Cytawa, J., Kutulas, G.: Influence of Chlorpromazine on Emotional Hyper-<br>reactivity Resulting from Septal Forebrain Injury . . . . .  | 389 |
| Dandiya, P. C., see Kulkarni, S. K. . . . .  | 367 |
| Davis, M., Bear, H. D.: Effects of N-N-Dimethyltryptamine on Retention of<br>Startle Response Habituation in the Rat . . . . .   | 29  |
| Davis, J. M., see Janowsky, D. S., <i>et al.</i> . . . .   | 295 |
| Dim, B. H., see Uhlenhuth, E. H., <i>et al.</i> . . . .  | 67  |
| Divac, I.: Drug-Induced Syndromes in Rats with Large, Chronic Lesions in<br>the Corpus striatum . . . . .  | 171 |
| Dobson, C. L., see Eleftheriou, B. E. . . . .  | 45  |
| Eades, C. G., see Martin, W. R. . . . .  | 93  |
| Eleftheriou, B. E., Dobson, C. L.: Effects of Neonatal and Adult Treatments<br>with Gonadal Hormones on Choline Acetylase Activity in Brain Regions<br>of Male Mice after Fighting . . . . .   | 45  |
| El-Yousef, M. K., see Janowsky, D. S., <i>et al.</i> . . . .   | 295 |
| Evangelista, A. M., Izquierdo, I.: Effects of Atropine on Avoidance Condi-<br>tioning: Interaction with Nicotine and Comparison with N-Methyl-Atropine . . . . .   | 241 |
| Ferraro, D. P., see Grisham, M. G. . . . .   | 163 |
| Frankenhaeuser, M., see Myrsten, A.-L., <i>et al.</i> . . . .  | 305 |
| Freedman, L. S., see Shopsin, B., <i>et al.</i> . . . .  | 11  |

|  |     |
|--|-----|
| Fried, P. A., see Shannon, M. E. . . . .   | 141 |
| Gaillard, J.-M., see . . . huler, M., <i>et al.</i> . . . .  | 123 |
| Gershon, S., see Shopsis, B., <i>et al.</i> . . . .  | 11  |
| Gianutsos, G., Abbatiello, E. R.: The Effect of Pre-Natal <i>Cannabis Sativa</i> on<br>Maze Learning Ability in the Rat . . . . .  | 117 |
| Gillich, U., see Becker-Carus, Ch., <i>et al.</i> . . . .  | 53  |
| Goldstein, M., see Shopsis, B., <i>et al.</i> . . . .  | 11  |
| Gottfries, C. G., see Jørgensen, A. . . . .  | 1   |
| Grant, L. D., see Cooper, B. R., <i>et al.</i> . . . .   | 99  |
| Graupner, O. K., Kálmán, E. V.: Die Flimmer-Verschmelzungs-Frequenz<br>unter dem Einfluß verschiedener Pharmaka. II. Phenothiazinderivate. 343                             |     |
| Grisham, M. G., Ferraro, D. P.: Biphase Effects of $\Delta^9$ -Tetrahydrocannabinol<br>on Variable Interval Schedule Performance in Rats . . . . .                         | 163 |
| Hartmann, E., see Schildkraut, J. J. . . . .   | 17  |
| Hepburn, E., Saunders, J. C.: Hippocampal Injections of Magnesium Pemoline<br>and the Extinction of a Bar Press Response in Rats . . . . .                                 | 157 |
| Henry, G. M., see Murphy, D. L., <i>et al.</i> . . . .   | 319 |
| Herman, Z. S., Kmiecik-Kolada, K., Słominska-Żurek, J., Szkilnik, R.: Central<br>Effects of Acetylcholine . . . . .  | 223 |
| Honecker, H., see Rating, D., <i>et al.</i> . . . .  | 349 |
| Howard, J. L., see Cooper, B. R., <i>et al.</i> . . . .  | 99  |
| Hughes, R. N., Syme, L. A.: The Role of Social Isolation and Sex in Deter-<br>mining Effects of Chlordiazepoxide and Methylphenidate on Exploratory<br>Behaviour . . . . . | 359 |
| Huntley, M. S., Jr.: Influences of Alcohol and S-R Uncertainty upon Spatial<br>Localization Time . . . . .   | 131 |
| Iwahara, S., Sakama, E.: Effects of Chlordiazepoxide upon Habituation of<br>Open-Field Behavior in White Rats . . . . .  | 285 |
| Izquierdo, I., see Evangelista, A. M. . . . .  | 241 |
| Janowsky, D. S., El-Youcef, M. K., Davis, J. M., Sekerke, H. J.: Cholinergic<br>Antagonism of Methylphenidate-Induced Stereotyped Behavior . . . . .                       | 295 |
| Johansson, G., see Myrsten, A.-L., <i>et al.</i> . . . .   | 305 |
| Jørgensen, A., Gottfries, C. G.: Pharmacokinetic Studies on Flupenthixol and<br>Flupenthixol Decanoate in Man Using Tritium Labelled Compounds . . . . .                   | 1   |
| Kálmán, E. V., see Graupner, O. K. . . . .   | 343 |
| Kimball, S. D., see Becker-Carus, Ch., <i>et al.</i> . . . .   | 53  |
| Kluwe, S., see Rating, D., <i>et al.</i> . . . .   | 349 |
| Kmiecik-Kolada, K., see Herman, Z. S., <i>et al.</i> . . . .   | 223 |
| Kulig, B. M., Calhoun, W. H.: Enhancement of Successive Discrimination<br>Reversal Learning by Methamphetamine . . . . .   | 233 |
| Kulkarni, S. K., Dandiya, P. C.: On the Mechanism of Potentiation of Amphet-<br>amine Induced Stereotyped Behaviour by Imipramine . . . . .                                | 367 |
| Kupfer, D. J., Bowers, M. B., Jr.: REM Sleep and Central Monoamine Oxidase<br>Inhibition . . . . .   | 183 |
| Kutolas, G., see Cytawa, J. . . . .  | 389 |
| Latz, A., see Atsmon, A., <i>et al.</i> . . . .  | 249 |
| Lowe, G., Williams, D. I.: The Effect of LSD-25 on Light-Reinforced Behaviour<br>in the Rat . . . . .  | 255 |
| Malpas, A.: Subjective and Objective Effects of Nitrazepam and Amylo-<br>barbitone Sodium in Normal Human Beings . . . . .   | 373 |
| Martin, W. R., Eades, C. G.: Cross Tolerance to Tryptamine in the LSD<br>Tolerant Dog . . . . .  | 93  |
| Matussek, N., see Becker-Carus, Ch., <i>et al.</i> . . . .   | 53  |
| McFarlain, R. A., Bloom, J. M.: The Effects of Para-Chlorophenylalanine on<br>Brain Serotonin, Food Intake, and U-Maze Behavior . . . . .                                  | 85  |

|  |     |
|--|-----|
| Murphy, D. L., Henry, G. M., Weingartner, H.: Catecholamines and Memory: Enhanced Verbal Learning during L-DOPA Administration . . . . .   | 319 |
| Myrsten, A.-L., Post, B., Frankenhaeuser, M., Johansson, G.: Changes in Behavioral and Physiological Activation Induced by Cigarette Smoking in Habitual Smokers . . . . .   | 305 |
| Niemegeers, C. J. E., see Wauquier, A. . . . .   | 191 |
| Post, B., see Myrsten, A.-L., <i>et al.</i> . . . .  | 305 |
| Randrup, A., see Ayhan, J. H. . . . .  | 203 |
| Rating, D., Broermann, I., Honecker, H., Kluwe, S., Coper, H.: Effect of Subchronic Treatment with (–) $\Delta^9$ -Trans-Tetrahydrocannabinol ( $\Delta^9$ -THC) on Food Intake, Body Temperature, Hexobarbital Sleeping Time and Hexobarbital Elimination in Rats . . . . . | 349 |
| Renzi, P., see Sansone, M., <i>et al.</i> . . . .  | 313 |
| Robins, A. H.: Phenothiazine Melanosis in Schizophrenic Patients . . . . .   | 327 |
| Rosecrans, J. A., see Schechter, M. D. . . . .   | 379 |
| Rosenblum, J., see Talley, W. H. . . . .   | 179 |
| Sakama, E., see Iwahara, S. . . . .  | 285 |
| Sansone, M., Renzi, P., Amposta, B.: Effects of Chlorpromazine and Chlor-diazepoxide on Discriminated Lever-Press Avoidance Behavior and Inter-trial Responding in Mice . . . . .  | 313 |
| Saunders, J. C., see Hepburn, E. . . . .   | 157 |
| Schechter, M. D., Rosecrans, J. A.: Nicotine as a Discriminative Cue in Rats: Inability of Related Drugs to Produce a Nicotine-Like Cueing Effect . . . . .  | 379 |
| Schildkraut, J. J., Hartmann, E.: Turnover and Metabolism of Norepinephrine in Rat Brain after 72 Hours on a D-Deprivation Island . . . . .  | 17  |
| Schuler, M., Gaillard, J.-M., Tissot, R.: Comparaison de l'effet somnogène de deux médicaments, le Ro 5-4200 et le Nitrazepam . . . . .  | 123 |
| Sekerke, H. J., see Janowsky, D. S., <i>et al.</i> . . . .   | 295 |
| Shader, R. I.: Sexual Dysfunction Associated with Mesoridazine Besylate (Serentil) . . . . .   | 293 |
| Shannon, M. E., Fried, P. A.: The Macro- and Microdistribution and Polymorphic Electroencephalographic Effects of $\Delta^9$ -Tetrahydrocannabinol in the Rat . . . . .  | 141 |
| Shopsin, B., Freedman, L. S., Goldstein, M., Gershon, S.: Serum Dopamine- $\beta$ -Hydroxylase (D $\beta$ H) Activity and Affective States . . . . .   | 11  |
| Sjöström, R.: Absence of Effect of Para-Chlorophenylalanine on 5-Hydroxy-indoleacetic Acid in Cerebrospinal Fluid in Man . . . . .   | 393 |
| Slominska-Zurek, J., see Herman, Z. S., <i>et al.</i> . . . .  | 223 |
| Steiner, M., see Atsmon, A., <i>et al.</i> . . . .   | 249 |
| Stephens, J. H., see Uhlenhuth, E. H., <i>et al.</i> . . . .   | 67  |
| Syme, L. A., see Hughes, R. N. . . . .   | 359 |
| Szkilnik, R., see Herman, Z. S., <i>et al.</i> . . . .   | 223 |
| Talley, W. H., Rosenblum, I.: Self Administration of Dextropropoxyphene by Rhesus Monkeys to the Point of Toxicity . . . . .   | 179 |
| Tissot, R., see Schuler, M., <i>et al.</i> . . . .   | 123 |
| Uhlenhuth, E. H., Stephens, J. H., Dim, B. H., Covi, L.: Diphenylhydantoin and Phenobarbital in the Relief of Psychoneurotic Symptoms: A Controlled Comparison . . . . .   | 67  |
| Warburton, D. M., Brown, K.: The Facilitation of Discrimination Performance by Physostigmine Sulphate . . . . .  | 275 |
| Wauquier, A., Niemegeers, C. J. E.: Intracranial Self-Stimulation in Rats as a Function of Various Stimulus Parameters. II. Influence of Haloperidol, Pimozide and Pipamperone on Medial Forebrain Bundle Stimulation with Monopolar Electrodes . . . . .                    | 191 |
| Weingartner, H., see Murphy, D. L., <i>et al.</i> . . . .  | 319 |
| Wijsenbeek, H., see Atsmon, A., <i>et al.</i> . . . .  | 249 |
| Williams, D. I., see Lowe, G. . . . .  | 255 |
| Indexed in Current Contents  |     |

## Subject Index

### A

Acetylcholine 223  
Activation 305  
Aggression 213  
Alcohol 131  
—, tolerance 265  
Alpha-methyltyrosine 53  
Amphetamines 171, 203, 213, 367, 379  
Amylobarbitone sodium 373  
Antagonism 111, 295  
Anticholinergic 111  
—, esterase 111  
—, depressants 213  
Arecoline 379  
Arousal 255  
Atropine 241  
Attention 275  
Audiogenic seizures 265  
Automatic behavior 53  
Avoidance behavior 313

### B

Barbiturates 213, 373  
Bar-press extinction 157  
—, performance 99  
Behavior 223, 305  
Benzodiazepines 373  
Body temperature 349

### C

Cannabis 117, 163  
Card dealing 373  
Catecholamines 11, 17, 53, 249  
Cerebrospinal fluid 183, 393  
Chlordiazepoxide 285, 313, 359  
Chlorpromazine 313, 327, 343, 389  
Choline acetylase 45  
Cholinergic 295  
Cigarette smoking 305  
Conditioning 53, 241  
Corpus striatum 171  
Cross tolerance 93

### D

D-deprivation 17  
Depot neuroleptic 1  
Depression 183, 213  
Digit symbol substitution 373  
Diphenylhydantoin 67  
Discrimination 275

Dissociation 285  
DMT (dimethyltryptamine) 29  
Dogs 93  
Dopamine 99, 183, 203  
Dopamine- $\beta$ -hydroxylase 11  
Dropouts 67  
Drug abuse 213  
—, -behavior interaction 111

### E

EEG 141  
—, recording, hippocampus activity 53  
Emotion 389  
Exploration 359

### F

Facilitation 275  
Falling asleep 123  
fighting 45, 213  
Flicker fusion (CFF) 343  
Flupenthixol 1  
—, decanoate 1  
Food intake 85, 349  
Frontal cortex 45

### G

General motor activity 111  
Gonadal hormones 45

### H

Habituation 29, 285  
Hallucinations 93  
Hexobarbitol elimination 349  
—, sleeping time 349  
Hippocampus 45, 53, 157  
Homovanillic acid 183  
Human subjects 1, 11, 67, 123, 131, 183, 249, 305, 319, 327, 343, 373, 393  
6-Hydroxydopamine 99  
5-Hydroxyindoleacetic acid 183, 223, 393  
5-Hydroxytryptamine 223  
Hypothalamus 45

### I

Imipramine 367  
Intertrial responses 313  
Intraventricular injection 223  
Isolation 359



**L**

L-DOPA 319  
Learning 53  
Learning set discrimination 233  
Light reinforcement 255  
Lobeline 379  
Locomotion 359  
LSD-25 255

**M**

Magnesium pemoline 157  
Marihuana 117, 163  
Maze 117  
Medial forebrain bundle 191  
Melanosis 327  
Memory 85, 157, 319  
Methamphetamine 223  
Methoxyhydroxyphenylglycol 249  
Methylphenidate 295, 359  
 $\alpha$ -Methyltyrosine 99  
 $\alpha$ -Methyl-*p*-tyrosine 319  
MHPG 11  
Mice 45, 111, 265, 313  
Monoamine oxidase inhibition 183  
Monopolar electrodes 191  
Morphine 203  
Motivation 85

**N**

Na-5-HT-rat 223  
Neuroleptics 1, 191  
Nicotine 241, 305, 379  
Nitrazepam 123, 373  
N-methylatropine 241  
Noradrenaline 203, 223  
Norepinephrine 17, 99

**O**

Open field behavior 285, 367  
Operant behavior 163

**P**

Para-chlorophenylalanine 85, 393  
Peripheral sympathetic activity 11  
Pharmacokinetics 1  
Phenelzine 183  
Phenobarbital 67  
—, thiazine 327  
Physostigmine 295  
—, sulphate 275  
Pigmentation 327  
Pre-natal 117  
—, -trial interval 241  
Probenecid 393  
Prognosis 67  
Propranolol 249  
Psychoneurosis 67  
Psychosis 249, 295, 327

**R**

Rats 17, 29, 53, 85, 99, 117, 141, 157,  
163, 171, 191, 203, 213, 223, 233,  
241, 255, 265, 275, 285, 295, 349,  
359, 367, 389  
Reaction time 131, 305  
Rearing 359  
REM sleep 17, 183  
Reserpine 99, 171  
Retention 29, 53  
Reversal learning 233  
Rigidity 171  
Ro 5-4200 123

**S**

Schedule of reinforcement 163  
Schizophrenia (dogs) 93  
Schizophrenics 1, 327  
Scopolamine-hydrobromide 275  
Sedative 111  
Self-stimulation 191  
Septum 389  
Serotonin 85  
Sex differences 359  
Shuttle-box avoidance 99  
Sleep 17, 123, 183, 349  
—, inducing 123  
Social isolation 359  
Startle response 29  
State-dependency 285, 379  
Stereotypy 171, 203, 295  
Steroids 45  
Stimulants 213  
Stimulus-response uncertainty 131  
Subjective ratings 373  
Synergism 111

**T**


Temporal maze skill 265  
Tetrahydrocannabinols 111  
THC ( $\Delta^9$ -tetrahydrocannabinol) 141,  
163  
Time-course of examination 343  
Tissue incorporation 141  
T-maze performance 99  
Tolerance 93  
(-)- $\Delta^8$ -Tetrahydrocannabinol 349  
Tryptamine 93

**U**

U-maze behavior 85

**V**

Various stimulus parameter combina-  
tions 191





## Instructions to Authors

1. Papers will be published in English, French or German.

2. Authors should submit manuscripts together with two copies. The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as clear and concise as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. Manuscripts should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The first page should bear:

the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief abstract in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should not exceed 200 words.

French and German articles should also have an English translation of the title.

7. Immediately following the abstract, some relevant key words should be supplied for subject indexing.

8. Articles dealing with original investigations should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. Footnotes should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The bibliography should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows; *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. *Psychopharmacologia (Berl.)* 14, 23—32 (1969).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: *Neuropsychopharmacology*. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, figures should be grouped, bearing in mind maximum display area is 108 × 177 mm (4 $\frac{1}{4}$  × 7"). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the block-maker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

M.G. Stringaris

# Die Haschischsucht

Pharmakologie · Geschichte · Psychopathologie  
Klinik · Soziologie

Zweite,  
überarbeitete  
Auflage

Von Professor  
Dr. M. G. Stringaris,  
Athen  
X, 150 Seiten. 1972  
Geheftet DM 14,80

■ Bitte Prospekt  
anfordern

Das klassische Werk des Autors über Haschisch, das 1939 in erster Auflage erschien, liegt jetzt in überarbeiteter Form in zweiter Auflage vor. Die damaligen Untersuchungen gingen von der theoretischen Frage nach Ähnlichkeiten zwischen den Erscheinungen des Haschischrausches bei Gewohnheitsrauchern und dem psychopathologischen Phänomen bei Geisteskrankheiten aus. Daneben beschrieb der Autor bereits damals die sozialhygienischen Eigenarten des Haschischgenusses: sein vorzugsweise im Jugendalter einsetzender Beginn, seine Expansions tendenz, die Folgen des chronischen Mißbrauchs und die Rolle des Haschisch als Wegbereiter für stärkere Rauschmittel, z. B. Heroin. Die in den letzten Jahren ausgebrochene Rauschgiftwelle löste Erschrecken, Protest und Ratlosigkeit aus; der Wunsch nach Information über dieses Thema erweckte Interesse für das seit langem vergriffene Buch. Die überarbeitete, zweite Auflage ergänzt die damaligen Erkenntnisse mit den inzwischen angesammelten Ergebnissen der Einzelforschung; sie berücksichtigt die aktuelle Situation der Haschischverbreitung und weist auf die große Bedeutung hin, die der Unterscheidung zwischen Traditions- und Expansionsländern des Haschischgenusses für das richtige Verständnis seiner Verbreitung zukommt.



**Springer-Verlag**  
**Berlin · Heidelberg · New York**

